Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease.With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.

Gritstone bio

A biotechnology company focused on developing mRNA-based vaccines and therapeutics.

Moderna, Inc.

Specializes in immune-driven medicine, utilizing its proprietary immune medicine platform for diagnosis and treatment.

Adaptive Biotechnologies Corporation

Focused on developing neoantigen-based T cell therapies for cancer treatment.

Neon Therapeutics, Inc.

Gritstone bio, Inc. is a clinical-stage biotechnology company focused on developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate, GRANITE, is a neoantigen-based immunotherapy in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate in Phase 2 clinical trials for the treatment of metastatic solid tumors. Additionally, it is working on a SARS-CoV-2 vaccine platform and a therapeutic vaccine candidate for HIV infection.

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Gritstone bio, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 8, 2024 10:51 PM	9f494820
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 8, 2024 10:51 PM	26777093
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	368cebf0
crunchbase profile	general	Nov 27, 2024 1:22 PM	336e2d8d
li profile	general	Feb 8, 2024 10:51 PM	d3d8431d
translate crunchbase fundingrounds	general
peers	general	Feb 8, 2024 10:51 PM	71941b54
news basic	general	Feb 8, 2024 10:51 PM	7ff1259f
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:GRITSTONEBIO

Gritstone bio, Inc.

Last Close

0.03

21/10 20:00

Market Cap

63.26M

Beta: -

Volume Today

55.25M

Avg: -